Pharmacokinetics and pharmacodynamics of drugs in neonates and children during Cardiopulmonary Bypass.
Recruiting
- Conditions
- congenital heart disease (CHD)1001039410007510
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 160
Inclusion Criteria
Pediatric patients undergoing open heart surgery for congenital heart disease with the use of CPB at the department of Cardiothoracic Surgery at the Erasmus Medical Centre.
Exclusion Criteria
No informed consent
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Determination of population pharmacokinetics of midazolam, propofol,<br /><br>sufentanil, pancuronium, ranitidine, furosemide, enoximone, and dobutamine in<br /><br>the pediatric population.<br /><br>Determination of the relationship between the pharmacokinetics of the<br /><br>medication and clinical parameters as age, cyanotic or acyanotic cardiac<br /><br>defects, cardiopulmonary bypass system used, pump flow rate, liver and renal<br /><br>function and protein concentrations.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Determination of the relationship between pharmacokinetics and the clinical<br /><br>effect of aforementioned medication. DNA analysis will be performed to evaluate<br /><br>the influence of gene polymorphisms on the pharmacodynamics of anesthetic and<br /><br>analgesic medication.<br /><br>Microcirculation measurements of the oromucosa before and after cardiopulmonary<br /><br>bypass. </p><br>